Inclusion Criteria:  Patients included in the CORIMUNO-19 cohort Patients hospitalized in conventional ward or in the ICU belonging to the following groups: OMS Progression scale 6, 7, 8 AND no acute pulmonary embolism on CT-scan performed in the preceding 72 hours no pulmonary evident bacterial coinfection or superinfection evaluated by non-invasive procedures (serology, antigens, nasopharynx PCR, sputum examination, blood cultures…)  Exclusion Criteria:  Patients in OMS progression class 9 Patients with exclusion criteria to the CORIMUNO-19 cohort Pregnancy Active cancer with ongoing treatment acute use of NIV for COPD exacerbation or cardiac decompensation associated to COVID-19 Oxygen patient requiring long-term oxygen before hospitalization Patient already included in an interventional research Risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery during the last 3 weeks Hypersensitivity to the active substance (bevacizumab) or to any of the excipients (sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide, water for injection Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies Persistant uncontrolled arterial hypertension after using to anti-hypertensive drugs Current documented bacterial infection not controlled by antibiotics. Active viral diseases (especially active herpes, chickenpox, shingles), Active tuberculosis or disseminated strongyloidiasis patient with known active hepatitis or with increased level of SGOT or SGPT ≥5N Patient with anormal laboratory results: Absolute neutrophil count (ANC) ≤ 1.0 x 109/L, Platelets (PLT) < 50 G /L